61 related articles for article (PubMed ID: 7647778)
1. Stop codon FGFR3 mutations in thanatophoric dwarfism type 1.
Rousseau F; Saugier P; Le Merrer M; Munnich A; Delezoide AL; Maroteaux P; Bonaventure J; Narcy F; Sanak M
Nat Genet; 1995 May; 10(1):11-2. PubMed ID: 7647778
[No Abstract] [Full Text] [Related]
2. The respiratory elastance ratio in thanatophoric dysplasia: A case report.
Aoki K; Kurosawa H; Shirasawa A; Shiomi Y; Seino Y
Pediatr Int; 2023; 65(1):e15534. PubMed ID: 36965046
[No Abstract] [Full Text] [Related]
3. Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1).
Rousseau F; el Ghouzzi V; Delezoide AL; Legeai-Mallet L; Le Merrer M; Munnich A; Bonaventure J
Hum Mol Genet; 1996 Apr; 5(4):509-12. PubMed ID: 8845844
[TBL] [Abstract][Full Text] [Related]
4. Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3.
Tavormina PL; Shiang R; Thompson LM; Zhu YZ; Wilkin DJ; Lachman RS; Wilcox WR; Rimoin DL; Cohn DH; Wasmuth JJ
Nat Genet; 1995 Mar; 9(3):321-8. PubMed ID: 7773297
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia.
Rousseau F; Bonaventure J; Legeai-Mallet L; Pelet A; Rozet JM; Maroteaux P; Le Merrer M; Munnich A
Nature; 1994 Sep; 371(6494):252-4. PubMed ID: 8078586
[TBL] [Abstract][Full Text] [Related]
6. Single-cell profiling of multiple myeloma reveals molecular response to FGFR3 inhibitor despite clinical progression.
Croucher DC; Devasia AJ; Abelman DD; Mahdipour-Shirayeh A; Li Z; Erdmann N; Tiedemann R; Pugh TJ; Trudel S
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36639200
[TBL] [Abstract][Full Text] [Related]
7. Neonatal Bone Disorders.
Saraff V; Nadar R; Shaw N
Front Pediatr; 2021; 9():602552. PubMed ID: 33889553
[TBL] [Abstract][Full Text] [Related]
8. Molecular investigations of development and diseases of the brain of higher mammals using the ferret.
Kawasaki H
Proc Jpn Acad Ser B Phys Biol Sci; 2017; 93(5):259-269. PubMed ID: 28496051
[TBL] [Abstract][Full Text] [Related]
9. Achondroplasia: Development, pathogenesis, and therapy.
Ornitz DM; Legeai-Mallet L
Dev Dyn; 2017 Apr; 246(4):291-309. PubMed ID: 27987249
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiological analyses of cortical malformation using gyrencephalic mammals.
Masuda K; Toda T; Shinmyo Y; Ebisu H; Hoshiba Y; Wakimoto M; Ichikawa Y; Kawasaki H
Sci Rep; 2015 Oct; 5():15370. PubMed ID: 26482531
[TBL] [Abstract][Full Text] [Related]
11. A case of thanatophoric dysplasia type 2: a novel mutation.
Gülaşı S; Atıcı A; Çelik Y
J Clin Res Pediatr Endocrinol; 2015 Mar; 7(1):73-6. PubMed ID: 25800480
[TBL] [Abstract][Full Text] [Related]
12. Diagnosis of chromosomal abnormalities in a patient with thanatophoric dysplasia (TD) type I: The first report describing an important association between cytogenetic findings and TD.
Turgut M; Demirhan O; Tunc E; Bucak IH; Canoz PY; Temiz F; Tumgor G
Am J Case Rep; 2012; 13():109-13. PubMed ID: 23569503
[TBL] [Abstract][Full Text] [Related]
13. Height matters-from monogenic disorders to normal variation.
Durand C; Rappold GA
Nat Rev Endocrinol; 2013 Mar; 9(3):171-7. PubMed ID: 23337954
[TBL] [Abstract][Full Text] [Related]
14. Sixteen years and counting: the current understanding of fibroblast growth factor receptor 3 (FGFR3) signaling in skeletal dysplasias.
Foldynova-Trantirkova S; Wilcox WR; Krejci P
Hum Mutat; 2012 Jan; 33(1):29-41. PubMed ID: 22045636
[TBL] [Abstract][Full Text] [Related]
15. Targeting mutant fibroblast growth factor receptors in cancer.
Greulich H; Pollock PM
Trends Mol Med; 2011 May; 17(5):283-92. PubMed ID: 21367659
[TBL] [Abstract][Full Text] [Related]
16. Genetic inactivation of ERK1 and ERK2 in chondrocytes promotes bone growth and enlarges the spinal canal.
Sebastian A; Matsushita T; Kawanami A; Mackem S; Landreth GE; Murakami S
J Orthop Res; 2011 Mar; 29(3):375-9. PubMed ID: 20922792
[TBL] [Abstract][Full Text] [Related]
17. FGFR3-related dwarfism and cell signaling.
Harada D; Yamanaka Y; Ueda K; Tanaka H; Seino Y
J Bone Miner Metab; 2009; 27(1):9-15. PubMed ID: 19066716
[No Abstract] [Full Text] [Related]
18. FGFR3 promotes synchondrosis closure and fusion of ossification centers through the MAPK pathway.
Matsushita T; Wilcox WR; Chan YY; Kawanami A; Bükülmez H; Balmes G; Krejci P; Mekikian PB; Otani K; Yamaura I; Warman ML; Givol D; Murakami S
Hum Mol Genet; 2009 Jan; 18(2):227-40. PubMed ID: 18923003
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of Spry1 in chondrocytes causes attenuated FGFR ubiquitination and sustained ERK activation resulting in chondrodysplasia.
Yang X; Harkins LK; Zubanova O; Harrington A; Kovalenko D; Nadeau RJ; Chen PY; Toher JL; Lindner V; Liaw L; Friesel R
Dev Biol; 2008 Sep; 321(1):64-76. PubMed ID: 18582454
[TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of MKK6 in chondrocytes of transgenic mice inhibits proliferation and delays endochondral bone formation.
Zhang R; Murakami S; Coustry F; Wang Y; de Crombrugghe B
Proc Natl Acad Sci U S A; 2006 Jan; 103(2):365-70. PubMed ID: 16387856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
